Abstract:
:ROS1 rearrangement is a validated therapeutic driver gene in non-small cell lung cancer (NSCLC) and represents a small subset (1-2%) of NSCLC. A total of 17 different fusion partner genes of ROS1 in NSCLC have been reported. The multi-targeted MET/ALK/ROS1 tyrosine kinase inhibitor (TKI) crizotinib has demonstrated remarkable efficacy in ROS1-rearranged NSCLC. Consequently, ROS1 detection assays include fluorescence in situ hybridization, immunohistochemistry, and real-time PCR. Next-generation sequencing (NGS) assay covers a range of fusion genes and approaches to discover novel receptor-kinase rearrangements in lung cancer. A 63-year-old male smoker with stage IV NSCLC (TxNxM1) was detected with a novel ROS1 fusion. Histological examination of the tumor showed lung adenocarcinoma. NGS analysis of the hydrothorax cellblocks revealed a novel CEP72-ROS1 rearrangement. This novel CEP72-ROS1 fusion variant is generated by the fusion of exons 1-11 of CEP72 on chromosome 5p15 to exons 23-43 of ROS1 on chromosome 6q22. The predicted CEP72-ROS1 protein product contains 1202 amino acids comprising the N-terminal amino acids 594-647 of CEP72 and C-terminal amino acid 1-1148 of ROS1. CEP72-ROS1 is a novel ROS1 fusion variant in NSCLC discovered by NGS and could be included in ROS1 detection assay, such as reverse transcription PCR. Pleural effusion samples show good diagnostic performance in clinical practice.
journal_name
Thorac Cancerjournal_title
Thoracic cancerauthors
Zhu YC,Zhou YF,Wang WX,Xu CW,Zhuang W,Du KQ,Chen Gdoi
10.1111/1759-7714.12617subject
Has Abstractpub_date
2018-05-01 00:00:00pages
652-655issue
5eissn
1759-7706issn
1759-7714journal_volume
9pub_type
相关文献
Thoracic Cancer文献大全abstract:BACKGROUND:Esophageal cancer has a high mortality rate, particularly in Asia, and there are obvious racial differences in regard to incidence. The purpose of our study was to assess the genetic susceptibility of functional single nucleotide polymorphisms in flap endonuclease-1 (FEN1) in esophageal squamous cell carcino...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12422
更新日期:2017-05-01 00:00:00
abstract:BACKGROUND:It has been reported that there are more circulating tumor cells (CTCs) in the pulmonary vein (PV) than in the peripheral blood; however, it is unclear whether the CTC count changes in the PV after resection of a lung lobe. METHODS:Thirty-three lung cancer patients were recruited for the study, including 17...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12925
更新日期:2019-02-01 00:00:00
abstract:BACKGROUND:This study evaluated the efficacy and safety of retreatment with anti-programmed death 1 (anti-PD-1) antibodies in patients with advanced non-small cell lung cancer (NSCLC) after prior treatment with anti-programmed death-ligand 1 (anti-PD-L1) antibodies. METHODS:Data (N = 15) on patients' characteristics, ...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13241
更新日期:2020-01-01 00:00:00
abstract::This report describes the case of a 17-year-old man who developed mediastinal growing teratoma syndrome following two cycles of chemotherapy, after an initial diagnosis of primary mediastinal nonseminomatous germ cell tumor. The large, rapidly-growing mediastinal tumor was completely resected in conjunction with right...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/1759-7714.13297
更新日期:2020-03-01 00:00:00
abstract::Pulmonary pleomorphic carcinoma (PPC) is a very rare type of primary lung cancer with an aggressive clinical course. Few reports have documented therapeutic options for PPC with EGFR mutations. Herein, we report a case of PPC with EGFR mutation treated with EGFR-tyrosine kinase inhibitors (TKIs). A 65-year-old Japanes...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/1759-7714.12646
更新日期:2018-06-01 00:00:00
abstract::The main recurrence pattern for lung cancer patients after radical surgery is distant metastasis. The probability of pancreatic metastasis in patients diagnosed with lung squamous cell carcinoma is 0.02%, with a poor prognosis. Chemotherapy is the preferred treatment for recurrence. Single lesions or oligometastasis c...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/1759-7714.13427
更新日期:2020-07-01 00:00:00
abstract::Bronchomediastinal fistula is an extremely rare complication resulting from diseases such as mediastinitis or mediastinal malignancies. In patients with lung cancer, bronchomediastinal fistula formation has rarely been reported, except during post-chemotherapy or post-radiation therapy complications. An 84-year-old vi...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/j.1759-7714.2012.00167.x
更新日期:2013-08-01 00:00:00
abstract::Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are widely used in patients with EGFR-mutant lung cancer. Meanwhile, thermal ablation such as microwave ablation has been an option for selected patients. Herein, we describe three cases of pneumothorax that occurred in microwave ablation (MWA) ...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/1759-7714.13466
更新日期:2020-07-01 00:00:00
abstract::Several authors have previously reported that patients with pulmonary combined large cell neuroendocrine cancer ( LCNEC) have a poor prognosis and there is no consensus on the treatment strategy for combined LCNEC as well as LCNEC. Here, we report the case of a long-term survivor with pulmonary combined LCNEC. The pat...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/1759-7714.13471
更新日期:2020-07-01 00:00:00
abstract::A clinical trial of immune checkpoint inhibitors for advanced non-small cell lung cancer reported an overall survival plateau with a long tail to the survival curve, suggesting that immune checkpoint inhibitors prolong survival. However, little evidence supports the efficacy of immune checkpoint inhibitors as neoadjuv...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/1759-7714.13663
更新日期:2020-11-01 00:00:00
abstract::Lung cancer is globally one of the leading causes of malignant tumor-related mortality and ranks as having the highest incidence found in men and second in women. Osimertinib is a drug used to target lung cancer but its toxicity is not fully understood. Here we present a case of lung adenocarcinoma in a 78-year-old ma...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/1759-7714.13127
更新日期:2019-07-01 00:00:00
abstract::A 78-year-old male with renal cell carcinoma was treated with combined immunotherapy of nivolumab and ipilimumab. After four courses of the treatment, a chest computed tomography (CT) revealed newly formed ground-glass opacities (GGOs) in both the lower lung lobes; drug-induced pneumonia was speculated. Eosinophil cou...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/1759-7714.13848
更新日期:2021-01-21 00:00:00
abstract::Immune checkpoint inhibitors that block the programmed death 1/programmed death ligand 1 pathways are widely used to treat advanced lung cancers. There are seldom cases of histologic transformation reported after treatment with immunotherapy. Here, we report the case of a 69-year-old man with stage IV lung squamous ce...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/1759-7714.13312
更新日期:2020-03-01 00:00:00
abstract:BACKGROUND:Our recent studies have indicated that miR-153-3p is downregulated in the esophageal squamous cell carcinoma (ESCC) cell lines and tissues. Upregulation of miR-153-3p was found to inhibit migration and invasion of ESCC cells. However, whether miR-153-3p regulates the cisplatin sensitivity in ESCC cells remai...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13326
更新日期:2020-03-01 00:00:00
abstract:BACKGROUND:This study aimed to explore the effects of HMGA2 on cell proliferation and metastases in lung cancer and its underlying mechanism. METHODS:HMGA2 expression in lung cancer tissues and its association with overall survival were analyzed based on data from a public database. The roles of HMGA2 were validated v...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12476
更新日期:2017-09-01 00:00:00
abstract:BACKGROUND:Eugenol, a natural compound available in Syzigium aromaticum (cloves), is exploited for various medicinal applications. Eugenol induces apoptosis and functions as an anti-cancer drug in several types of tumors. We investigated the tumor suppressive role and potential mechanisms of eugenol in human lung cance...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12508
更新日期:2018-01-01 00:00:00
abstract:BACKGROUND:In cases of EGFR-tyrosine kinase inhibitor (TKI) failure, re-biopsy may be useful to understand resistance mechanisms and guide further treatment decisions. However, performing re-biopsy is challenging because of several hurdles. We assessed the feasibility of re-biopsy in advanced non-small cell lung cancer...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12762
更新日期:2018-07-01 00:00:00
abstract::Acquired respiratory-digestive tract fistulas occur with abnormal communication between the airways and digestive tract, causing the interflow of gas and liquid. Despite advances in surgical methods and the development of multimodal therapy in recent years, patients with acquired respiratory-digestive tract fistulas c...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12856
更新日期:2018-11-01 00:00:00
abstract:BACKGROUND:The aim of this study was to investigate the feasibility of using a combination of apatinib in the treatment of non-small cell lung cancer. Apatinib is a tyrosine kinase inhibitor which selectivelyacts on vascular endothelial growth factor receptor 2 (VEGFR-2) and has shown good efficacy in a variety of mali...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13162
更新日期:2019-10-01 00:00:00
abstract::Most tumor cells show different metabolic pathways than normal cells. Even under the conditions of sufficient oxygen, they produce energy by a high rate of glycolysis followed by lactic acid fermentation in the cytosol, which is known as aerobic glycolysis or the Warburg effect. Lung cancer is a malignant tumor with o...
journal_title:Thoracic cancer
pub_type: 杂志文章,评审
doi:10.1111/1759-7714.12148
更新日期:2015-01-01 00:00:00
abstract:BACKGROUND:Most non-small cell lung cancer (NSCLC) patients relapse on anaplastic lymphoma kinase-tyrosine kinase inhibitor (ALK-TKI) therapy because of acquired resistance. Rebiopsy is recommended to provide optimal therapy after relapse for some ALK-TKI therapies; however, little clinical data exists on the clinical ...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13143
更新日期:2019-09-01 00:00:00
abstract:BACKGROUND:As its etiology and pathogenesis is obscure, illustrating the molecular mechanism of lung cancer has become a serious and urgent task. Studies have shown that fumarate hydratase (FH) is a tumor suppressor related to tumorigenesis, development, and invasion. Our aim was to analyze the biological information o...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12127
更新日期:2014-11-01 00:00:00
abstract:BACKGROUND:Osimertinib (AZD9291) is a third-generation EGFR-tyrosine kinase inhibitor (TKI) that selectively inhibits the activating EGFR mutation and T790M mutation, and is currently used globally to treat EGFR-mutant non-small cell lung cancer (NSCLC). However, acquired resistance to osimertinib is inevitable. METHO...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13255
更新日期:2020-01-01 00:00:00
abstract::A 69-year-old woman visited our hospital complaining of right chest pain. Chest computed tomography showed a 55 × 45 mm tumor in the right upper lobe. Bronchoscopy revealed displaced anomalous B 1 and B 2+3 arising from the right main bronchus, and the patient was diagnosed with lung adenocarcinoma by transbronchial l...
journal_title:Thoracic cancer
pub_type:
doi:10.1111/1759-7714.12362
更新日期:2016-09-01 00:00:00
abstract:BACKGROUND:Uniportal video-assisted thoracoscopic surgery (VATS) is being more widely used in lung cancer, yet reports on its application in pneumonectomies are limited. This study aimed to evaluate the safety and feasibility of uniportal video-assisted thoracoscopic left pneumonectomy for lung cancer. METHODS:A serie...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13728
更新日期:2021-01-06 00:00:00
abstract:INTRODUCTION:VATS pulmonary segmentectomy is increasingly proposed as a parenchyma-sparing resection for tumors smaller than 2 cm in diameter. The aim of this study was to compare short-term oncological results and local control in solid non-small cell lung cancers (NSCLCs) <2 cm surgically treated by intentional VATS ...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13766
更新日期:2020-12-03 00:00:00
abstract:BACKGROUND:Immunotherapy is a new paradigm for the treatment of non-small-cell lung cancer (NSCLC), and targeting the PD-1 or PD-L1 pathway is a promising therapeutic option. Although PD-1/PD-L1 inhibitors are more effective than standard chemotherapy in lung cancer, clinicians are afraid to actively use them because o...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.12877
更新日期:2018-11-01 00:00:00
abstract:BACKGROUND:Plasmid construction of small fragments of interest (such as insertion of small fragment marker genes, expression of shRNA, siRNA, etc) is the basis of many biomolecular experiments. Here, we describe a method to clone short DNA into vectors by polymerase chain reaction (PCR), named one-step PCR cloning. Our...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13660
更新日期:2020-11-01 00:00:00
abstract:BACKGROUND:Next-generation sequencing (NGS) has been implemented in clinical oncology to analyze multiple genes and to guide targeted therapy; however, little is known about the performance of the Oncomine Dx Target Test compared with conventional single gene tests for detecting EGFR mutations. The objective of this st...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13767
更新日期:2020-12-12 00:00:00
abstract:BACKGROUND:To compare the efficiency and toxicity of bevacizumab by intrapleural or intravenous infusion in the management of malignant pleural effusion in patients with non-small-cell lung cancer (NSCLC). METHODS:Sensitizing mutation negative NSCLC patients with malignant pleural effusion were randomized into two gro...
journal_title:Thoracic cancer
pub_type: 杂志文章
doi:10.1111/1759-7714.13238
更新日期:2020-01-01 00:00:00